Mianserine Viatris

Mianserin, the active ingredient in Mianserine Viatris, is a tetracyclic antidepressant presented as an oral tablet for oral use. It is prescribed for the treatment of major depressive disorder in adult patients and works by modulating neurotransmitter activity to improve mood and alleviate depressive symptoms.

GNH USA supplies Mianserine Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑compliant shipments to a global network of healthcare providers.

Mianserin is indicated for major depressive disorder, a condition characterized by persistent low mood and loss of interest.

Major depressive disorder: alleviates depressive symptoms and improves functional outcomes in adult patients.

Mianserin may cause a range of adverse reactions, which are commonly classified by frequency.

Common Side Effects: - Sedation or drowsiness - Weight gain or increased appetite - Dry mouth - Constipation - Dizziness - Orthostatic hypotension

Serious or Rare Side Effects: - Agranulocytosis or severe blood dyscrasias - Seizures - Cardiac arrhythmias - Severe hypotension - Suicidal ideation or behavior - Hepatotoxicity

When prescribing Mianserin, clinicians should consider several safety precautions to minimize risk.

Monitor blood pressure: watch for orthostatic hypotension, especially during dose initiation. Assess for suicidal thoughts: evaluate mood changes regularly, particularly in early treatment. Use caution in elderly: increased sensitivity to sedation and falls. Avoid abrupt discontinuation: taper dose to reduce withdrawal symptoms. Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Mianserin can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of severe hypertensive crisis. - Selective serotonin reuptake inhibitors (SSRIs) or other serotonergic agents: potential serotonin syndrome. - CNS depressants (e.g., benzodiazepines, alcohol): enhanced sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - Antihypertensive drugs: additive blood pressure‑lowering effect. - Anticholinergic medications: increased anticholinergic burden. - CYP2D6 inhibitors (e.g., fluoxetine, quinidine): may raise Mianserin plasma levels.